Program seeks Council approval for a parent initiative titled “Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)”.
The objective of the NIH REAP program is to stimulate research in educational institutions that offer baccalaureate or advanced degrees, but that have not been major recipients of NIH support. REAP grants create opportunities for scientists and institutions, otherwise unlikely to participate extensively in NIH research programs, to contribute to the Nation’s biomedical and behavioral research effort. REAP grants are intended to support small-scale research projects proposed by faculty members at eligible, domestic health professional schools or graduate schools, to engage undergraduate and/or graduate students in meritorious projects in biomedical or behavioral research, and to strengthen the research environment of the applicant institution. Eligible health professional schools include schools or colleges of nursing, medicine, dentistry, osteopathy, pharmacy, veterinary medicine, public health, optometry, allied health, chiropractic, naturopathy, podiatry, rehabilitation medicine, physical therapy, orthotics & prosthetics, kinesiology, biomedical engineering, occupational therapy and psychology.
The first NIH REAP Funding Opportunity Announcements (FOAs) were published in 2019, comprising a clinical trial not allowed version, and a clinical trial required version. NICHD Program seeks approval to reissue the REAP FOA that supports clinical trials. NIDCR is tasked with reissuing the CT not allowed REAP FOA.
The REAP clinical trial required program enables qualified scientists to receive support for investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. Minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm. A mechanistic clinical trial is designed to explore or understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention. Proposed studies should be hypothesis-driven and produce research data that informs the core scientific postulate and advances scientific knowledge.
Previous FOA: PAR-19-135, Research Enhancement Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required); published December 21, 2018, expires January 8, 2022.
Companion FOA: PAR-19-134, Research Enhancement Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed); published December 21, 2018, expires January 8, 2022.
Program seeks approval to reissue the initiative PAR-19-135.
Program Contact
Mahua Mukhopadhyay
Developmental Biology and Structural Variation Branch (DBSVB)
Back to Concept Review by Council
BACK TO TOP